azacitidine has been researched along with Chromosome Inversion in 8 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (12.50) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (37.50) | 29.6817 |
| 2010's | 4 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Aguilera, P; Badenas, C; Combalia, A; Costa, D; Gaya, A; Guijarro, F; Jorge, S; Podlipnik, S; Rozman, M; To-Figueras, J | 1 |
| Akasaka, T; Honjo, G; Izumi, K; Kishimori, C; Maesako, Y; Ohno, H; Okamori, S; Okumura, A; Takeoka, K | 1 |
| Bohannan, Z; Borthakur, G; Bueso-Ramos, C; Chang, KS; DiNardo, CD; Estécio, MR; Fang, Z; Garcia-Manero, G; Kantarjian, H; Kondo, K; Maddipoti, S; Pierce, SA; Stevenson, W; Wei, Y; Yang, H | 1 |
| Keating, GM | 1 |
| Alimena, G; Breccia, M; Cannella, L; Federico, V; Loglisci, G; Mancini, M; Nanni, M; Salaroli, A; Santopietro, M | 1 |
| Aventín, A; Brunet, S; Carnicer, MJ; Lasa, A; Nomdedéu, JF; Orantes, V; Pena, J; Serrano, E; Sierra, J | 1 |
| Camitta, B; Carroll, AJ; Chang, M; Gresik, MV; Raimondi, SC; Ravindranath, Y; Steuber, CP; Weinstein, H | 1 |
| Katz, AJ | 1 |
1 review(s) available for azacitidine and Chromosome Inversion
| Article | Year |
|---|---|
Azacitidine: a review of its use in higher-risk myelodysplastic syndromes/acute myeloid leukaemia.
Topics: Antimetabolites, Antineoplastic; Azacitidine; Bone Marrow; Bone Marrow Cells; Chromosome Inversion; Combined Modality Therapy; Erythrocyte Transfusion; Erythroid Precursor Cells; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Myelodysplastic Syndromes; Prognosis; Randomized Controlled Trials as Topic; Remission Induction; Risk Assessment; Stem Cell Transplantation; Transplantation Conditioning; Treatment Outcome | 2009 |
7 other study(ies) available for azacitidine and Chromosome Inversion
| Article | Year |
|---|---|
Acquired erythropoietic uroporphyria secondary to myelodysplastic syndrome with chromosome 3 alterations: a case report.
Topics: Aged; Antimetabolites, Antineoplastic; Azacitidine; Blood Transfusion; Bone Marrow; Bone Marrow Transplantation; Chromosome Inversion; Chromosomes, Human, Pair 3; Humans; Late Onset Disorders; Male; Myelodysplastic Syndromes; Porphyria, Erythropoietic; Porphyrins; Skin; Treatment Outcome | 2018 |
inv(2)(p23q13)/RAN-binding protein 2 (RANBP2)-ALK fusion gene in myeloid leukemia that developed in an elderly woman.
Topics: Aged; Anaplastic Lymphoma Kinase; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Chromosome Inversion; Chromosomes, Human, Pair 2; Cytarabine; Daunorubicin; Diagnosis, Differential; Female; Humans; Leukemia, Myeloid, Acute; Leukemia, Myelomonocytic, Chronic; Molecular Chaperones; Nuclear Pore Complex Proteins; Oncogene Proteins, Fusion; Receptor Protein-Tyrosine Kinases; Treatment Outcome | 2014 |
RUNX3 promoter hypermethylation is frequent in leukaemia cell lines and associated with acute myeloid leukaemia inv(16) subtype.
Topics: Adult; Aged; Azacitidine; Cell Line, Tumor; Chromosome Inversion; Core Binding Factor Alpha 3 Subunit; Decitabine; DNA Methylation; Gene Expression Regulation, Leukemic; Humans; Leukemia, Myeloid, Acute; Middle Aged; Promoter Regions, Genetic; Transcriptional Activation | 2015 |
5'-azacitidine in myelodysplastic syndromes with inversion of chromosome 3.
Topics: Antimetabolites, Antineoplastic; Azacitidine; Chromosome Inversion; Chromosomes, Human, Pair 3; Humans; In Situ Hybridization, Fluorescence; Male; Middle Aged; Myelodysplastic Syndromes; Treatment Outcome | 2011 |
Epigenetic-based treatments emphasize the biologic differences of core-binding factor acute myeloid leukemias.
Topics: Adult; Azacitidine; Biomarkers, Tumor; Chromatin Assembly and Disassembly; Chromosome Inversion; Chromosomes, Human, Pair 16; Chromosomes, Human, Pair 21; Chromosomes, Human, Pair 8; Core Binding Factor Alpha 2 Subunit; Decitabine; DNA Methylation; DNA Modification Methylases; Enzyme Inhibitors; Epigenesis, Genetic; Gene Expression Profiling; Gene Expression Regulation, Leukemic; Histone Deacetylase Inhibitors; Humans; Hydroxamic Acids; Leukemia, Myeloid, Acute; Mutation; Oligonucleotide Array Sequence Analysis; Oncogene Proteins, Fusion; Promoter Regions, Genetic; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; RUNX1 Translocation Partner 1 Protein; Translocation, Genetic; Tumor Cells, Cultured; U937 Cells | 2008 |
Prognostic factors in children and adolescents with acute myeloid leukemia (excluding children with Down syndrome and acute promyelocytic leukemia): univariate and recursive partitioning analysis of patients treated on Pediatric Oncology Group (POG) Study
Topics: Adolescent; Analysis of Variance; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Bone Marrow Transplantation; Child; Chromosome Aberrations; Chromosome Inversion; Chromosomes, Human; Cohort Studies; Combined Modality Therapy; Cytarabine; Disease-Free Survival; Doxorubicin; Etoposide; Female; Follow-Up Studies; Humans; Leukemia, Myeloid; Life Tables; Male; Multicenter Studies as Topic; Prognosis; Proportional Hazards Models; Randomized Controlled Trials as Topic; Remission Induction; Risk Assessment; Risk Factors; Survival Analysis; Thioguanine; Translocation, Genetic; Treatment Failure; Treatment Outcome; United States | 2000 |
Genotoxicity of 5-azacytidine in somatic cells of Drosophila.
Topics: Animals; Azacitidine; Chromosome Inversion; Crosses, Genetic; Drosophila melanogaster; Heterozygote; Mutation; Phenotype; Recombination, Genetic | 1985 |